{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:13:48Z","timestamp":1779923628810,"version":"3.53.1"},"reference-count":43,"publisher":"Baishideng Publishing Group Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2016,3,28]]},"DOI":"10.3748\/wjg.v22.i12.3418","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:13:05Z","timestamp":1505693585000},"page":"3418-3431","source":"Crossref","is-referenced-by-count":17,"title":["Daclatasvirvs<\/i>telaprevir plus peginterferon alfa\/ribavirin for hepatitis C virus genotype 1"],"prefix":"10.3748","volume":"22","author":[{"given":"Ira","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brygida","family":"Knysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lueth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Zarebska-Michaluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Diago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Linda","family":"Zignego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacov","family":"Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzhamal","family":"Abdurakhmanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Shafran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Bruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander James","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kopit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Michener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"World Health Organization. Hepatitis C key facts. WHO factsheet No 164. (Updated April 2014, accessed June 23, 2015). Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/<\/ext-link>."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:S45-S57.","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"ref6","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. (Updated July 7, 2014, accessed June 23, 2015). Available from: http:\/\/www.hcvguidelines.org\/fullreport7<\/ext-link>."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/827849"},{"key":"ref9","unstructured":"Bristol-Myers Squibb. Japan approves first all-oral, interferon- and ribavirin-free hepatitis C treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) dual regimen. (Updated July 7, 2014, accessed June 23, 2015). Available from: http:\/\/news.bms.com\/press-release\/japan-approves-first-all-oral-interferon-and-ribavirin-free-hepatitis-c-treatment-dakl<\/ext-link>."},{"key":"ref10","unstructured":"Bristol-Myers Squibb. European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection. (Updated August 27, 2014, accessed June 23, 2015). Available from: http:\/\/news.bms.com\/press-release\/rd-news\/european-commission-approves-bristol-myers-squibbs-daklinza-daclatasvir-across<\/ext-link>."},{"key":"ref11","unstructured":"Gilead Sciences, Inc . Harvoni (ledipasvir and sofosbuvir) prescribing information. (Updated March 2015, accessed June 23 2015). Available from: http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liverdisease\/harvoni\/harvoni_pi.pdf<\/ext-link>."},{"key":"ref12","unstructured":"Gilead Sciences, Inc . Harvoni (ledipasvir and sofosbuvir) [summary of product characteristics] Cambridge, United Kingdom: Gilead Sciences International Ltd; 2014;."},{"key":"ref13","unstructured":"Janssen Therapeutics. OLYSIO™ (simeprevir) prescribing information. (Updated April 2015, accessed June 23, 2015). Available from: https:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf<\/ext-link>."},{"key":"ref14","unstructured":"Janssen Therapeutics. Olysio (simeprevir) summary of product characteristics. (Updated April 7, 2015, accessed June 23, 2015). Available from: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140514128513\/anx_128513_en.pdf<\/ext-link>."},{"key":"ref15","unstructured":"AbbVie , Inc . Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) prescribing information. (Updated March 2015, accessed June 23, 2015). Available from: http:\/\/www.rxabbvie.com\/pdf\/viekirapak_pi.pdf<\/ext-link>."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.047"},{"key":"ref19","unstructured":"Vertex Pharmaceuticals. Incivek (telaprevir) prescribing information. (Updated October 2013, accessed June 23, 2015). Available from: http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf<\/ext-link>."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71002-3"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24609"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.007"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307498"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60934-8"},{"key":"ref29","unstructured":"Bristol-Myers Squibb. Health Canada approves Daklinza TM (daclatasvir) for the treatment of chronic hepatitis C infection across multiple genotypes including genotype 3. (Accessed October 14, 2015). Available from: http:\/\/www.bmscanada.ca\/en\/news\/release\/health-canada-approves-daklinza-daclatasvir-for-the-treatment-of-chronic-hepatitis-c-infection-acros<\/ext-link>."},{"key":"ref30","unstructured":"Bristol-Myers Squibb. ."},{"key":"ref31","unstructured":"Fleiss J, Levin B, Paik M. Statistical Methods for Rates and Proportions. 3rd ed Hoboken: John Wiley & Sons; 2013;."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02283.x"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hep.2012.11.012"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26388."},{"key":"ref35","unstructured":"Reddy KR, Thuluvath PJ, Kumada Y, Toyota J, Chayama K, Levin J, Lawitz E, Gadano A, Ghesquiere W, Gerken G. Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies Hoboken: Wiley-Blackwell; 2014;1154A-1155A."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3860"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3868"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i12\/3418.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:41:16Z","timestamp":1570102876000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i12\/3418.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,3,28]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v22.i12.3418","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}